《盈利預喜》藥明康德(02359.HK)料去年純利最多增70%至50億人民幣
藥明康德(02359.HK)發盈喜,預計2021年年度營業收入介乎228.19-229.02億人民幣(下同),按年增加38%-38.5%;實現歸屬股東淨利潤介乎49.73-50.32億元,增長68%-70%;扣除非經常性損益,預計淨利潤介乎40.07-40.55億元,增長68%-70%。
2021年,公司始終貫徹執行「跟隨分子」的戰略,持續建設「一體化,端到端」合同研究、開發及生產組織業務,訂單需求旺盛,推動全年營業收入加速增長;測試業務下實驗室分析及測試業務和臨牀CRO/SMO業務、生物學業務以及化學業務下小分子藥物發現服務,也繼續保持了強勁的增長勢頭。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.